Across TCGA pan-cancer cohorts, C1QL2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated C1QL2 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in uterine carcinosarcoma (UCS), where higher C1QL2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C1QL2 expression acts as an unfavorable survival marker.
UCS are the cancer types where C1QL2 Mutation most reproducibly stratifies survival.